Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Current Deferred Revenue (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Current Deferred Revenue for 10 consecutive years, with $44.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 32.64% year-over-year to $44.4 million, compared with a TTM value of $44.4 million through Dec 2025, down 32.64%, and an annual FY2025 reading of $44.4 million, down 32.64% over the prior year.
  • Current Deferred Revenue was $44.4 million for Q4 2025 at Wave Life Sciences, down from $46.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $150.1 million in Q4 2023 and bottomed at $8.7 million in Q3 2021.
  • Average Current Deferred Revenue over 5 years is $67.4 million, with a median of $49.1 million recorded in 2025.
  • The sharpest move saw Current Deferred Revenue crashed 89.86% in 2021, then skyrocketed 375.5% in 2023.
  • Year by year, Current Deferred Revenue stood at $37.1 million in 2021, then fell by 14.93% to $31.6 million in 2022, then surged by 375.5% to $150.1 million in 2023, then crashed by 56.04% to $66.0 million in 2024, then crashed by 32.64% to $44.4 million in 2025.
  • Business Quant data shows Current Deferred Revenue for WVE at $44.4 million in Q4 2025, $46.5 million in Q3 2025, and $51.6 million in Q2 2025.